A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Xisomab 3G3 in Healthy Adult Subjects

Trial Profile

A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Xisomab 3G3 in Healthy Adult Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 May 2017

At a glance

  • Drugs Xisomab 3G3 (Primary)
  • Indications Thrombosis
  • Focus Adverse reactions
  • Sponsors Aronora
  • Most Recent Events

    • 22 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.
    • 22 May 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.
    • 22 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top